Dr. Ulrich Thibaut
Dr. Ulrich Thibaut studied Pharmacy and Pharmaceutical Chemistry at Tübingen University in Germany. On graduating, and after qualifying as a Pharmacist, Ulrich obtained a PhD in Pharmaceutical Chemistry and subsequently joined Byk Gulden GmbH (which later became ALTANA Pharma AG) as a research scientist. He served in various scientific and managerial roles in Research and Development and was appointed Executive Vice President Global R&D and member of the Executive Board of Management of ALTANA Pharma AG in 2004.
After the sale of ALTANA Pharma AG to Nycomed in 2006 Ulrich joined Drägerwerk AG in Lübeck, a global leader in the medical and safety device industry as Chief Technology Officer and Member of the Executive Board. His responsibilities included the global R&D organization of Dräger Medical AG, Dräger Safety AG and Drägerwerk AG’s basic research and development as well as the patent department.
In 2010, Ulrich joined Octapharma AG in Switzerland as Executive Board Member, with responsibility for the global R&D organization of the Octapharma Group. During his more than five years at Octapharma, several new products were successfully launched by the Company, including Nuwiq®, a recombinant FVIII produced in a human cell line and Panzyga®, a new IVIG product.
Ulrich has a broad managerial and scientific background from more than 27 years of R&D work in the healthcare industry and a proven track record of several large and successful product launches emerging from the R&D organizations he led.
Today, Ulrich teaches at the Swiss Federal Institute of Technology and is a consultant to the pharmaceutical and medical device industry.